_id
690f3d09ccc777a4e85d1a78
Ticker
CDNA
Name
CareDx Inc
Exchange
NASDAQ
Address
8000 Marina Boulevard, South San Francisco, CA, United States, 94005
Country
USA
Sector
Healthcare
Industry
Diagnostics & Research
Currency
USD
Website
https://caredx.com
Description
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI, a transplant quality tracking software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Last Close
19.8
Volume
245496
Current Price
19.99
Change
0.9595959595959481
Last Updated
2025-11-29T11:17:16.509Z
Image
data:image/webp;base64,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
Ipo Date
2014-07-17T00:00:00.000Z
Market Cap
951165632
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.995
Sentiment Sources
3
Rating
4.125
Target Price
22.3333
Strong Buy
4
Buy
1
Hold
3
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
100055000
Cost Of Revenue
31309000
Gross Profit
68746000
Operating Expenses
66733999
Operating Income
2012000
Interest Expense
-
Pretax Income
1660000
Net Income
1675000
Eps
0.03117045137977166
Dividends Per Share
-
Shares Outstanding
51432639
Income Tax Expense
-15000
EBITDA
6823000
Operating Margin
2.0108940082954376
Total Other Income Expense Net
-352000
Cash
91435000
Short Term Investments
102782000
Receivables
47844000
Inventories
28328000
Total Current Assets
300280000
Property Plant Equipment
54892000
Total Assets
432307000
Payables
11597000
Short Term Debt
6432000
Long Term Debt
-
Total Liabilities
121167000
Equity
311140000
Depreciation
5163000
Change In Working Capital
18858000
Cash From Operations
37358000
Capital Expenditures
1305000
Cash From Investing
12349000
Cash From Financing
-26478000
Net Change In Cash
23223000
PE
13.9609
PB
3.394602453718583
ROE
0.5383428681622421
ROA
0.38745613649559224
FCF
36053000
Fcf Percent
0.3603318175003748
Piotroski FScore
4
Health Score
65
Deep Value Investing Score
6.5
Defensive Investing Score
7
Dividend Investing Score
3
Economic Moat Investing Score
6.3
Garp Investing Score
5
Growth Investing Score
3.5
Momentum Investing Score
5.5
Net Net Investing Score
4
Quality Investing Score
5
Value Investing Score
6.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
100055000
Quarters > 0 > income Statement > cost Of Revenue
31309000
Quarters > 0 > income Statement > gross Profit
68746000
Quarters > 0 > income Statement > operating Expenses
66733999
Quarters > 0 > income Statement > operating Income
2012000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
1660000
Quarters > 0 > income Statement > net Income
1675000
Quarters > 0 > income Statement > eps
0.03117045137977166
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
53736790
Quarters > 0 > income Statement > income Tax Expense
-15000
Quarters > 0 > income Statement > EBITDA
6823000
Quarters > 0 > income Statement > operating Margin
2.0108940082954376
Quarters > 0 > income Statement > total Other Income Expense Net
-352000
Quarters > 0 > balance Sheet > cash
91435000
Quarters > 0 > balance Sheet > short Term Investments
102782000
Quarters > 0 > balance Sheet > receivables
47844000
Quarters > 0 > balance Sheet > inventories
28328000
Quarters > 0 > balance Sheet > total Current Assets
300280000
Quarters > 0 > balance Sheet > property Plant Equipment
54892000
Quarters > 0 > balance Sheet > total Assets
432307000
Quarters > 0 > balance Sheet > payables
11597000
Quarters > 0 > balance Sheet > short Term Debt
6432000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
121167000
Quarters > 0 > balance Sheet > equity
311140000
Quarters > 0 > cash Flow > net Income
1675000
Quarters > 0 > cash Flow > depreciation
5163000
Quarters > 0 > cash Flow > change In Working Capital
18858000
Quarters > 0 > cash Flow > cash From Operations
37358000
Quarters > 0 > cash Flow > capital Expenditures
1305000
Quarters > 0 > cash Flow > cash From Investing
12349000
Quarters > 0 > cash Flow > cash From Financing
-26478000
Quarters > 0 > cash Flow > net Change In Cash
23223000
Quarters > 0 > ratios > PE
0.03117045137977166
Quarters > 0 > ratios > PB
3.394602453718583
Quarters > 0 > ratios > ROE
0.5383428681622421
Quarters > 0 > ratios > ROA
0.38745613649559224
Quarters > 0 > ratios > FCF
36053000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.3603318175003748
Quarters > 0 > health Score
65
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
86679000
Quarters > 1 > income Statement > cost Of Revenue
28658000
Quarters > 1 > income Statement > gross Profit
58021000
Quarters > 1 > income Statement > operating Expenses
69142000
Quarters > 1 > income Statement > operating Income
-11121000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-8685000
Quarters > 1 > income Statement > net Income
-8568000
Quarters > 1 > income Statement > eps
-0.15777624183694858
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
54304754
Quarters > 1 > income Statement > income Tax Expense
-117000
Quarters > 1 > income Statement > EBITDA
-5718000
Quarters > 1 > income Statement > operating Margin
-12.83009725539058
Quarters > 1 > income Statement > total Other Income Expense Net
2436000
Quarters > 1 > balance Sheet > cash
68212000
Quarters > 1 > balance Sheet > short Term Investments
118043000
Quarters > 1 > balance Sheet > receivables
67362000
Quarters > 1 > balance Sheet > inventories
27915000
Quarters > 1 > balance Sheet > total Current Assets
307296000
Quarters > 1 > balance Sheet > property Plant Equipment
57306000
Quarters > 1 > balance Sheet > total Assets
444257000
Quarters > 1 > balance Sheet > payables
9863000
Quarters > 1 > balance Sheet > short Term Debt
6342000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
116887000
Quarters > 1 > balance Sheet > equity
327370000
Quarters > 1 > cash Flow > net Income
-8568000
Quarters > 1 > cash Flow > depreciation
5053000
Quarters > 1 > cash Flow > change In Working Capital
3760000
Quarters > 1 > cash Flow > cash From Operations
9895000
Quarters > 1 > cash Flow > capital Expenditures
1007000
Quarters > 1 > cash Flow > cash From Investing
23397000
Quarters > 1 > cash Flow > cash From Financing
-53811000
Quarters > 1 > cash Flow > net Change In Cash
-20532000
Quarters > 1 > ratios > PE
-0.15777624183694858
Quarters > 1 > ratios > PB
3.260408528179125
Quarters > 1 > ratios > ROE
-2.6172221034303695
Quarters > 1 > ratios > ROA
-1.9286133926983706
Quarters > 1 > ratios > FCF
8888000
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
0.1025392540292343
Quarters > 1 > health Score
39
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
84685000
Quarters > 2 > income Statement > cost Of Revenue
28415000
Quarters > 2 > income Statement > gross Profit
56270000
Quarters > 2 > income Statement > operating Expenses
69644000
Quarters > 2 > income Statement > operating Income
-13374000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-10295000
Quarters > 2 > income Statement > net Income
-10353000
Quarters > 2 > income Statement > eps
-0.18734236925649653
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
55262459
Quarters > 2 > income Statement > income Tax Expense
58000
Quarters > 2 > income Statement > EBITDA
-3074000
Quarters > 2 > income Statement > operating Margin
-15.792643325264214
Quarters > 2 > income Statement > total Other Income Expense Net
3079000
Quarters > 2 > balance Sheet > cash
88745000
Quarters > 2 > balance Sheet > short Term Investments
142172000
Quarters > 2 > balance Sheet > receivables
71485000
Quarters > 2 > balance Sheet > inventories
22929000
Quarters > 2 > balance Sheet > total Current Assets
350239000
Quarters > 2 > balance Sheet > property Plant Equipment
59119000
Quarters > 2 > balance Sheet > total Assets
489638000
Quarters > 2 > balance Sheet > payables
8072000
Quarters > 2 > balance Sheet > short Term Debt
6205000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
110289000
Quarters > 2 > balance Sheet > equity
379349000
Quarters > 2 > cash Flow > net Income
-10353000
Quarters > 2 > cash Flow > depreciation
4940000
Quarters > 2 > cash Flow > change In Working Capital
-30978000
Quarters > 2 > cash Flow > cash From Operations
-26584000
Quarters > 2 > cash Flow > capital Expenditures
1630000
Quarters > 2 > cash Flow > cash From Investing
1325000
Quarters > 2 > cash Flow > cash From Financing
-643000
Quarters > 2 > cash Flow > net Change In Cash
-25979000
Quarters > 2 > ratios > PE
-0.18734236925649653
Quarters > 2 > ratios > PB
2.863283234290851
Quarters > 2 > ratios > ROE
-2.7291491476186835
Quarters > 2 > ratios > ROA
-2.114419223998137
Quarters > 2 > ratios > FCF
-28214000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-0.333164078644388
Quarters > 2 > health Score
34
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
86579000
Quarters > 3 > income Statement > cost Of Revenue
28178000
Quarters > 3 > income Statement > gross Profit
58401000
Quarters > 3 > income Statement > operating Expenses
70322000
Quarters > 3 > income Statement > operating Income
-11921000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
87868000
Quarters > 3 > income Statement > net Income
78010000
Quarters > 3 > income Statement > eps
1.3398771644722836
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
58221755
Quarters > 3 > income Statement > income Tax Expense
-171000
Quarters > 3 > income Statement > EBITDA
-7233000
Quarters > 3 > income Statement > operating Margin
-13.76892780004389
Quarters > 3 > income Statement > total Other Income Expense Net
13176000
Quarters > 3 > balance Sheet > cash
114689000
Quarters > 3 > balance Sheet > short Term Investments
145964000
Quarters > 3 > balance Sheet > receivables
64605000
Quarters > 3 > balance Sheet > inventories
19503000
Quarters > 3 > balance Sheet > total Current Assets
351832000
Quarters > 3 > balance Sheet > property Plant Equipment
57892000
Quarters > 3 > balance Sheet > total Assets
491050000
Quarters > 3 > balance Sheet > payables
7686000
Quarters > 3 > balance Sheet > short Term Debt
6103000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
112617000
Quarters > 3 > balance Sheet > equity
378433000
Quarters > 3 > cash Flow > net Income
78010000
Quarters > 3 > cash Flow > depreciation
4688000
Quarters > 3 > cash Flow > change In Working Capital
-86712000
Quarters > 3 > cash Flow > cash From Operations
21889000
Quarters > 3 > cash Flow > capital Expenditures
1522000
Quarters > 3 > cash Flow > cash From Investing
-2111000
Quarters > 3 > cash Flow > cash From Financing
-903000
Quarters > 3 > cash Flow > net Change In Cash
19282000
Quarters > 3 > ratios > PE
1.3398771644722836
Quarters > 3 > ratios > PB
3.0239133334698614
Quarters > 3 > ratios > ROE
20.61395280009936
Quarters > 3 > ratios > ROA
15.886365950514204
Quarters > 3 > ratios > FCF
20367000
Quarters > 3 > ratios > Piotroski FScore
3
Quarters > 3 > ratios > fcf Percent
0.23524180228461866
Quarters > 3 > health Score
88
Valuation > metrics > PE
13.9609
Valuation > metrics > PB
3.394602453718583
Valuation > final Score
76.05397546281417
Valuation > verdict
6.6% Overvalued
Profitability > metrics > ROE
0.5383428681622421
Profitability > metrics > ROA
0.5578127081390702
Profitability > metrics > Net Margin
0.01674079256408975
Profitability > final Score
5
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.3894291958603844
Risk > metrics > Interest Coverage
0.389695913228743
Risk > final Score
62
Risk > verdict
High
Liquidity > metrics > Current Ratio
16.655388540684452
Liquidity > metrics > Quick Ratio
15.084142215319762
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
47.39591471820875
Prev Valuations > 1
80
Prev Valuations > 2
69.76086666530139
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
100
Prev Risks > 0
45
Prev Risks > 1
53
Prev Risks > 2
59
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-12T15:05:02.305Z
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI, a transplant quality tracking software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AThere is no doubt that Caredx Inc (CDNA) ticks all the boxes. setenews.com
Read more →Russell Investments Group Ltd. Has $5.06 Million Stock Holdings in CareDx, Inc. $CDNA - MarketBeat
12/6/2025
Russell Investments Group Ltd. Has $5.06 Million Stock Holdings in CareDx, Inc. $CDNA MarketBeat
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$22.3333
Analyst Picks
Strong Buy
4
Buy
1
Hold
3
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 106.39% of the total shares of CareDx Inc
1.
Vanguard Group Inc(9.2257%)
since
2025/06/30
2.
BlackRock Inc(8.7511%)
since
2025/06/30
3.
Amvescap Plc.(4.7784%)
since
2025/06/30
4.
BAMCO Inc(4.576%)
since
2025/06/30
5.
ARK Genomic Revolution ETF(4.1456%)
since
2025/08/28
6.
State Street Corp(4.0959%)
since
2025/06/30
7.
ARK Investment Management LLC(3.9457%)
since
2025/06/30
8.
ARK Genomic Revolution(3.8511%)
since
2025/06/30
9.
Ophir Asset Management Pty Ltd(3.5565%)
since
2025/06/30
10.
Baron Discovery Strategy(3.4201%)
since
2025/06/30
11.
Baron Discovery Institutional(3.4201%)
since
2025/06/30
12.
Hood River Capital Management LLC(3.3178%)
since
2025/06/30
13.
Vanguard Total Stock Mkt Idx Inv(3.0186%)
since
2025/07/31
14.
Gagnon Securities LLC(2.91%)
since
2025/06/30
15.
Geode Capital Management, LLC(2.4865%)
since
2025/06/30
16.
iShares Russell 2000 ETF(2.4753%)
since
2025/08/31
17.
Sumitomo Mitsui Trust Group Inc(2.3239%)
since
2025/06/30
18.
Amova Asset Management Americas, Inc(2.3214%)
since
2025/06/30
19.
Fred Alger Management, LLC(2.3179%)
since
2025/06/30
20.
Renaissance Technologies Corp(2.1713%)
since
2025/06/30
21.
Goldman Sachs Group Inc(2.1241%)
since
2025/06/30
22.
Next Century Growth Investors LLC(2.1144%)
since
2025/06/30
23.
Jacobs Levy Equity Management, Inc.(2.0523%)
since
2025/06/30
24.
Connor Clark & Lunn Inv Mgmt Ltd(2.0334%)
since
2025/06/30
25.
Dimensional Fund Advisors, Inc.(1.8088%)
since
2025/06/30
26.
Hood River Small-Cap Growth Instl(1.7874%)
since
2025/06/30
27.
Amova ARK Pstv Chg Innovt P JPY Acc(1.7788%)
since
2025/07/31
28.
Alger Small Cap Focus Composite(1.7303%)
since
2025/06/30
29.
Alger Small Cap Focus I(1.7303%)
since
2025/06/30
30.
SPDR® S&P Biotech ETF(1.6336%)
since
2025/08/31
31.
Citadel Advisors Llc(1.4855%)
since
2025/06/30
32.
Strategic Advisers U.S. Total Stock(1.2872%)
since
2025/07/31
33.
Vanguard Small Cap Index(1.2029%)
since
2025/07/31
34.
Vanguard Institutional Extnd Mkt Idx Tr(1.123%)
since
2025/07/31
35.
Fidelity Small Cap Index(1.0286%)
since
2025/06/30
36.
Invesco Small Cap Equity Composite(1.0019%)
since
2025/06/30
37.
Invesco Small Cap Equity A(1.0019%)
since
2025/06/30
38.
iShares Russell 2000 Growth ETF(0.9021%)
since
2025/08/31
39.
First Eagle Small Cap Opportunity I(0.7286%)
since
2025/07/31
40.
JNL Multi-Manager Small Cap Growth A(0.7245%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.